Real-world performance of the NeuMoDxTM HCV Quant Test for quantification of hepatitis C virus (HCV)-RNA

Nadine Lübke,Andreas Walker,Martin Obermeier,Jennifer Camdereli,Martha Paluschinski,Lara Walotka,Anna-Kathrin Schupp,Inga Tometten,Sandra Hauka,Eva Heger,Jörg Timm
DOI: https://doi.org/10.1016/j.jviromet.2024.114937
IF: 2.623
2024-04-12
Journal of Virological Methods
Abstract:Quantification of hepatitis C virus (HCV)-RNA in serum or plasma samples is an essential parameter in HCV diagnostics. Here, the NeuMoDxTMMolecular System (Qiagen) was tested for the most common HCV genotypes and compared to the cobas c6800 system (Roche). HCV-RNA from 131 plasma/serum samples from chronically infected patients was determined in parallel on the NeuMoDx and c6800 systems. Linearity was analysed using the four most common HCV genotypes (1-4) in our cohort. The coefficient of variation (CV) within (intra-assay) and between (inter-assay) runs was calculated based on HCV-RNA concentration. Quantitative HCV-RNA results were highly correlated on both test systems (R2=0.7947; y=0.94x+0.37). On average, the NeuMoDx and c6800 HCV RNA levels showed a mean difference of only 0.05 log10 IU/mL but with a broad distribution (±1.2 2xSD). The NeuMoDx demonstrated very good linearity across all HCV genotypes tested at concentrations between 1.7 and 6.2 log10 IU/mL (R2 range: 0.9257-0.9991) with the highest mean coefficient of determination for genotype 1 (R2=0.9909). The mean intra- and inter-assay CV for both serum and plasma samples was <5%. The NeuMoDx HCV-RNA Assay demonstrates high subtype-independent comparability, linearity, and reproducibility for the quantification of HCV-RNA in serum and plasma samples from chronically infected patients.
biochemical research methods,biotechnology & applied microbiology,virology
What problem does this paper attempt to address?